Experts also present latest findings on stem cell transplant, other cellular therapies
- Real-World Study highlights CD19 CAR T-cell therapy for large B-cell lymphoma
- Donor race, ethnicity and age impact stem cell transplant outcomes
- Dr. Holtan featured on panel discussing better pathways to transplant
BUFFALO, N.Y. — Experts from Roswell Park Comprehensive Cancer Center have been invited to share their recent discoveries at the 2026 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), to be held Feb. 4-7 at the Salt Palace Convention Center in Salt Lake City, Utah. Drawing more than 5,000 clinicians and researchers from all over the world, the conference focuses on the latest advances in hematopoietic stem cell transplantation, cellular therapy and gene therapy for blood cancers.
Invited talk by CAR T-Cell pioneer Dr. Marco Davila reveals strategy for overcoming resistance
A preclinical study led by senior author Marco Davila, MD, PhD, Senior Vice President and Associate Director for Translational Research at Roswell Park, suggests a strategy for overcoming resistance to CAR T-cell therapy while reducing the risk of serious side effects, including cytokine release syndrome, neutropenia and immune cell-associated hematologic toxicity (ICAHT). A pioneer in the field, Dr. Davila played a key role in developing some of the first CAR T-cell therapies for blood cancers.
Investigators focused on how macrophages – white blood cells capable of surrounding and “eating” cancer cells – can play a role in suppressing CAR T cells’ cancer-killing function and increasing toxicity. They discovered that interferon gamma (IFN-γ), a signaling protein called a cytokine that is produced by CAR T cells, causes the macrophages to express inducible nitric oxide synthase (iNOS), which in turn suppresses the CAR T cells’ cancer-killing function…